Does treatment (Tx) for mental health illness (MHI) impact prostate cancer (PC) Tx and outcomes?

• DOI: 10.1200/jco.2025.43.5_suppl.318
• Publication Date: 2025-02-18T14:35:11Z
• Authors: Zachary Klaassen; Jessica L. Janes; Joshua Parrish; Sydney McIntire; Rashid K. Sayyid; Edward Machen; Amanda Marie De H...; Cristiane Decat B...; Stephen B. Williams; Martha K Terris; Stephen J. Freedland

318 Background: We previously showed that men with MHI are 20% less likely to be diagnosed PC, but when diagnosed, nearly 2x more have aggressive PC compared non-MHI (ASCO 2023). Subsequently, we prior Dx receive definitive treatment (DTx) however poorer post-Tx surveillance adherence and increased risk of biochemical recurrence (BCR; ASCO 2024). However, among whether impacts or outcomes has yet determined. The objective was test the association between (i) Tx time from receipt DTx, (ii) (prior DTx end) surveillance, (iii) BCR treated men. Methods: This national, retrospective study used a cohort males who were active users VA (≥2 encounters provider within 5-yr period, 2000-2020) age 40-80. Men included if following had no malignancy. Competing risks models (time-dependent covariate) (radical prostatectomy (RP) radiotherapy (RT)). Logistic regression (≥3 PSAs first year at least 1 PSA in each for next 4 consecutive years) Results: 62,019 (n=57,373 Tx) included. MHI-treated than without MHI-Tx both univariable (HR: 1.11, 95% CI: 1.06-1.15) multivariable 1.18, 1.13-1.23) analysis. Among (n=13,260), odds adhering did not differ vs non-treated (OR: 1.01, 0.92-1.11) 1.03, 0.94-1.14) an interaction present Dx: adhere earlier years (e.g., 2001 – OR: 1.54, 1.22-1.94) later 2015 0.85, 0.74-0.98). Risk lower vs. 0.86, 80, 0.93) 0.95, 0.87-1.03) Conclusions: received their untreated MHI, there difference post these groups. There also models. suggests is important receiving does impact subsequent outcomes.